Electrophysiologic Mechanisms of Ketamine Antidepressant Response
(Ketamine-sEEG Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms.
Participants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg/kg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.
Who Is on the Research Team?
Carl Hacker, MD, PhD
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Adults undergoing clinically indicated sEEG monitoring for epilepsy who have at least mild depressive symptoms will receive a single intravenous ketamine infusion (0.5 mg/kg over 40 minutes). Neural, behavioral, and symptom assessments will be performed before and approximately 24 hours after infusion to evaluate electrophysiologic correlates of antidepressant response.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.